Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0205700 (ash)
 15,125 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ethanol-insoluble components were extracted from fresh garlic with 0.9% NaCl solution containing streptomycin and penicillin. This extract, containing approximately 10% sugar, 0.3% nitrogen, and 0.4% ash, was termed garlic sugar solution. This garlic sugar solution (Medium 1) was used as the suspending medium for Ehrlich ascites tumor cells attenuated with allicin, the main principle of garlic, and 0.9% NaCl solution containing streptomycin and penicillin (Medium 2) was also used as the suspending medium. Mice of DDD strain were immunized with the attenuated tumor cells suspended in Medium 1 or 2. After immunization, the immunized and control mice were challenged intraperitoneally with viable Ehrlich ascites tumorcells. Animals immunized with the attenuated tumor cells suspended in Medium 1 acquired significantly stronger resistance against the tumor cells than animals immunized with those suspended in Medium 2.
 ...
PMID:Adjuvant action of garlic sugar solution in animals immunized with Ehrlich ascites tumor cells attenuated with allicin. 118 76

Bagasse fly ash, a waste from the sugar industry, was converted into an effective adsorbent and was used for the removal of DDD [2,2-Bis(4-chlorophenyl)-1,1-dichloroethane] and DDE [2,2-Bis(4-chlorophenyl)-1,1-dichloroethene] pesticides from wastewater. The DDD and DDE are removed by the developed adsorbent up to 93% at pH 7.0, with the adsorbent dose of 5 g/l of particle size 200-250 microns at 30 degrees C. The removal of these two pesticides was achieved up to 97-98% in column experiments at a flow rate of 0.5 ml/min. The adsorption was found to be exothermic in nature. The bagasse fly ash system has been used for the removal of DDD and DDE from the wastewater. The developed system is very useful, economic, and reproducible.
 ...
PMID:Removal of DDD and DDE from wastewater using bagasse fly ash, a sugar industry waste. 1125 90

This study has investigated a panel of immunomarkers in non-small cell lung carcinoma (NSCLC). Unsupervised hierarchical clustering analysis was used to investigate the possibility of identifying different subgroups in NSCLC based on their molecular expression profile rather than morphological features. A tissue microarray consisting of 284 cases of NSCLC was constructed. Immunohistochemistry was used to detect the presence of 18 biomarkers including synaptophysin, chromogranin, bombesin, NSE, GFI1, ASH-1, p53, p63, p21, p27, E2F-1, cyclin D1, Bcl-2, TTF-1, CEA, HER2/neu, cytokeratin 5/6, and pancytokeratin. Univariate analysis of all 18 markers for prognostic significance was performed. Immunohistochemical scoring data for NSCLC were analysed by unsupervised hierarchical clustering analysis. Kaplan-Meier survival curves were plotted for the different cluster groups of lung tumours identified by this method. Analysis of the three different World Health Organization (WHO) subtypes (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) of NSCLC individually showed that different markers were significant in different subtypes. For example, p53 and p63 were significant for squamous cell carcinoma (p = 0.007 and p = 0.03, respectively), whereas cyclin D1 and HER2/neu were significant prognostic markers for adenocarcinoma (p = 0.025 and p = 0.015, respectively). These markers were not significant prognostic predictors for NSCLC as a group. Hierarchical clustering analysis of NSCLC produced four separate cluster groups, although the vast majority of cases were found in two cluster groups, one dominated by squamous cell carcinoma and the other by adenocarcinoma. The clinical outcomes of cases from the four cluster groups were not significantly different. Prognostic indicators vary between different morphological subtypes of NSCLC. Unsupervised hierarchical clustering analysis, based on an extended immunoprofile, identifies two main cluster groups corresponding to adenocarcinoma and squamous cell carcinoma; cases of large cell carcinomas are assigned to one of these two groups based on their molecular phenotype.
 ...
PMID:Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. 1530 43

Hypertrophic cardiomyopathy (HCM) is classified as a primary cardiomyopathy. HCM is a clinically heterogeneous but relatively common autosomal dominant genetic heart disease that probably is the most frequently occurring cardiomyopathy. HCM is characterized morphologically and defined by a hypertrophied, nondilated left ventriculum (LV) in the absence of another systemic or cardiac disease that is capable of producing the magnitude of wall thickening evident (e.g., systemic hypertension, aortic valve stenosis). Most HCM patients have the propensity to develop dynamic obstruction to LV outflow under resting or physiologically provocable conditions, produced by systolic anterior motion of the mitral valve with ventricular septal contact. The phenotypic features of HCM may develop at any age from infancy to adulthood, and are characterized by a great heterogeneity in the extent, magnitude, and distribution of left ventricular hypertrophy. Hypertrophic obstructive cardiomyopathy (HOCM) often leads to heart failure, severe ischemia, severe symptoms and death. Determination of the exact site of the hypertrophy and of the obstruction of the left ventricular outflow tract, in asymmetric septal hypertrophy, establishes which is the best treatment strategy. In the treatment of HOCM, drug therapy with negatively inotropic drugs, percutaneous transluminal septal myocardial ablation by alcohol-induced septal branch occlusion, surgical myectomy and DDD pacemaker therapy are considered the therapeutical options. We present a case of an obstructive hypertrophic cardiomyopathy in an 84-year-old Italian woman with a left ventricular outflow tract (LVOT) peak gradient with the Valsalva maneuver of 188 mm Hg and with a history of first episode of syncope.
 ...
PMID:Revelation of an obstructive hypertrophic cardiomyopathy in an elderly patient. 1918 3